Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates
Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules we...
Saved in:
Published in | Journal of medicinal chemistry Vol. 63; no. 17; pp. 9603 - 9622 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
WASHINGTON
American Chemical Society
10.09.2020
Amer Chemical Soc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group. |
---|---|
AbstractList | Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody-drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group.Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody-drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group. Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group. Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody-drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of and experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group. |
Author | Chen, Jinhua Wai, John Zhang, Donglu Kozak, Katherine R Cruz-Chuh, Josefa dela Lewis Phillips, Gail D Go, Mary Ann Yu, Shang-Fan Staben, Leanna R Xu, Zijin Xu, Keyang Ng, Carl Pillow, Thomas H del Rosario, Geoff Dragovich, Peter S Wei, BinQing Khojasteh, S. Cyrus Guo, Jun Rowntree, Rebecca K Li, Guangmin |
AuthorAffiliation | Genentech, Inc WuXi AppTec Co., Ltd |
AuthorAffiliation_xml | – name: Genentech, Inc – name: WuXi AppTec Co., Ltd |
Author_xml | – sequence: 1 givenname: Leanna R surname: Staben fullname: Staben, Leanna R organization: Genentech, Inc – sequence: 2 givenname: Jinhua surname: Chen fullname: Chen, Jinhua organization: WuXi AppTec Co., Ltd – sequence: 3 givenname: Josefa dela surname: Cruz-Chuh fullname: Cruz-Chuh, Josefa dela organization: Genentech, Inc – sequence: 4 givenname: Geoff surname: del Rosario fullname: del Rosario, Geoff organization: Genentech, Inc – sequence: 5 givenname: Mary Ann surname: Go fullname: Go, Mary Ann organization: Genentech, Inc – sequence: 6 givenname: Jun surname: Guo fullname: Guo, Jun organization: Genentech, Inc – sequence: 7 givenname: S. Cyrus surname: Khojasteh fullname: Khojasteh, S. Cyrus organization: Genentech, Inc – sequence: 8 givenname: Katherine R surname: Kozak fullname: Kozak, Katherine R organization: Genentech, Inc – sequence: 9 givenname: Guangmin surname: Li fullname: Li, Guangmin organization: Genentech, Inc – sequence: 10 givenname: Carl surname: Ng fullname: Ng, Carl organization: Genentech, Inc – sequence: 11 givenname: Gail D surname: Lewis Phillips fullname: Lewis Phillips, Gail D organization: Genentech, Inc – sequence: 12 givenname: Thomas H surname: Pillow fullname: Pillow, Thomas H organization: Genentech, Inc – sequence: 13 givenname: Rebecca K surname: Rowntree fullname: Rowntree, Rebecca K organization: Genentech, Inc – sequence: 14 givenname: John surname: Wai fullname: Wai, John organization: WuXi AppTec Co., Ltd – sequence: 15 givenname: BinQing surname: Wei fullname: Wei, BinQing organization: Genentech, Inc – sequence: 16 givenname: Keyang surname: Xu fullname: Xu, Keyang organization: Genentech, Inc – sequence: 17 givenname: Zijin surname: Xu fullname: Xu, Zijin organization: WuXi AppTec Co., Ltd – sequence: 18 givenname: Shang-Fan surname: Yu fullname: Yu, Shang-Fan organization: Genentech, Inc – sequence: 19 givenname: Donglu surname: Zhang fullname: Zhang, Donglu organization: Genentech, Inc – sequence: 20 givenname: Peter S orcidid: 0000-0001-7372-2862 surname: Dragovich fullname: Dragovich, Peter S email: dragovich.peter@gene.com organization: Genentech, Inc |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32787101$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUsGO0zAUtNAitlv4A4R8XIRSbMdNUm5Ld4GVVqISC9foxXlpXSV21naEsif-gf_go_gS3G3LgQNwsqWZefPsmTNyYqxBQp5zNuNM8Neg_GzbYa022M2YYixb8EdkwueCJbJg8oRMGBMiEZlIT8mZ91vGWMpF-oScpiIvcs74hPz4NPqAHQSt6BdwOl6sobahq9E529oKzb2tNdxjrw3S89Xby5fJpe7Q0RWMrYWarjaj18ru9tAKWrpytkcXNHp63fWggqdXTRMhNVIwNb21LTqodKvDuHMKG6RL6xz63ppamzW9MEFXth5_fvt-6YZ1RM12WENA_5Q8bqD1-OxwTsnnd1e3yw_Jzcf318uLmwQklyGpFFRpxlEsUoy-TS4hPjyvoRZVreYyrbio80iCeZFmgqHM55CKrJC5aBY5pFNyvp_bO3s3oA9lp73CtgWDdvClkKlkGSuiwZS8OFCHKsZR9k534Mby-MeR8GpP-IqVbbzSaBT-psVQ5jmXiziPMSkiu_h_9lKHh8CWdjAhSt_spcpZ7x02pTrgwYFuS87KXXPK2Jzy2Jzy0Jwoln-Ij57_kLG97AG1gzMxlr9LfgE2h98c |
CitedBy_id | crossref_primary_10_1038_s41467_023_44533_z crossref_primary_10_1021_jacs_4c03529 crossref_primary_10_1039_D2NJ03037C crossref_primary_10_1016_j_ejmech_2024_116233 crossref_primary_10_1021_acs_jcim_1c01130 crossref_primary_10_1038_s41392_022_00947_7 crossref_primary_10_1021_acs_bioconjchem_2c00611 crossref_primary_10_1002_advs_202306309 crossref_primary_10_1016_j_cell_2022_05_029 crossref_primary_10_1016_j_ejmech_2024_116709 crossref_primary_10_1016_j_ejmech_2024_116556 crossref_primary_10_1016_j_apsb_2023_06_015 |
Cites_doi | 10.1016/j.yexmp.2010.01.006 10.1021/mp500762u 10.1158/1078-0432.CCR-18-1300 10.1158/1535-7163.MCT-18-1302 10.1002/anie.201200447 10.1126/scitranslmed.aac9459 10.1371/journal.pone.0146311 10.1021/bc0502917 10.1021/jm030897l 10.1038/s41375-018-0278-7 10.2174/1568026619666190401112517 10.1182/blood-2018-99-118198 10.1158/0008-5472.CAN-13-1436 10.1039/c1cs15071e 10.1002/anie.201510610 10.1016/j.molimm.2014.09.014 10.1021/acsmedchemlett.9b00310 10.1182/blood-2013-03-491506 10.1158/1535-7163.MCT-17-0296 10.1182/bloodadvances.2018020107 10.1021/jm970530e 10.1158/0008-5472.CAN-08-1776 10.1021/acsmedchemlett.6b00233 10.3390/ijms20051115 10.1158/1535-7163.MCT-16-0641 10.1182/blood-2018-99-118133 10.1055/s-1986-31738 10.1158/1535-7163.MCT-16-0233 10.1158/0008-5472.CAN-08-2250 10.1007/978-1-4939-9929-3_4 10.1016/S0960-894X(98)00609-X 10.1073/pnas.63.1.78 10.1158/1538-7445.AM2018-2792A 10.1158/1078-0432.CCR-18-0333 10.1021/acs.jmedchem.7b00736 10.1021/acs.jmedchem.5b00201 10.1021/bi901655t 10.3390/catal10040443 10.1111/cas.12966 10.1002/adsc.200303203 10.1158/0008-5472.CAN-05-4489 10.1021/acs.bioconjchem.5b00430 10.1021/acsmedchemlett.9b00240 10.1016/j.nucmedbio.2014.07.005 10.1021/ja101845m 10.1016/j.ejmech.2019.06.044 10.1158/0008-5472.CAN-15-1795 10.1021/bi034313t 10.1021/acs.bioconjchem.7b00791 |
ContentType | Journal Article |
DBID | AAYXX CITATION 17B 1KM AOWDO BLEPL DTL EGQ CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1021/acs.jmedchem.0c00691 |
DatabaseName | CrossRef Web of Knowledge Index Chemicus Web of Science - Science Citation Index Expanded - 2020 Web of Science Core Collection Science Citation Index Expanded Web of Science Primary (SCIE, SSCI & AHCI) Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef Web of Science MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Web of Science |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 1KM name: Index Chemicus url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC sourceTypes: Enrichment Source Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-4804 |
EndPage | 9622 |
ExternalDocumentID | 32787101 000571493400042 10_1021_acs_jmedchem_0c00691 c500932642 |
Genre | Journal Article |
GroupedDBID | - .K2 55A 5GY 5RE 5VS 7~N AABXI ABFLS ABMVS ABOCM ABPTK ABUCX ACGFS ACJ ACS AEESW AENEX AFEFF ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 DU5 EBS ED ED~ F5P GNL IH9 IHE JG JG~ K2 L7B LG6 P2P ROL TN5 UI2 VF5 VG9 W1F WH7 X XFK YZZ ZY4 --- -~X 4.4 6P2 AAHBH AAYXX ABBLG ABJNI ABLBI ABQRX ACGFO ADHLV AGXLV AHGAQ CITATION CUPRZ GGK IH2 XSW YQT 17B 1KM BLEPL DTL GROUPED_WOS_WEB_OF_SCIENCE ABTAH CGR CUY CVF ECM EIF NPM YIN 7X8 |
ID | FETCH-LOGICAL-a414t-bcab361e293ecacf74a1237dad2bdc543b12d7caba583620e475a3268472f97a3 |
IEDL.DBID | ACS |
ISICitedReferencesCount | 14 |
ISICitedReferencesURI | https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000571493400042 |
ISSN | 0022-2623 1520-4804 |
IngestDate | Fri Jul 11 09:23:15 EDT 2025 Wed Feb 19 02:30:19 EST 2025 Fri Aug 29 16:12:15 EDT 2025 Wed Jul 09 16:15:16 EDT 2025 Thu Apr 24 22:59:42 EDT 2025 Tue Jul 01 01:09:51 EDT 2025 Sat Sep 12 13:17:16 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 17 |
Keywords | CANCER-CELLS TARGET DIMER POTENCY DNA CROSS-LINKING RELEASE |
Language | English |
License | https://doi.org/10.15223/policy-029 https://doi.org/10.15223/policy-037 https://doi.org/10.15223/policy-045 |
LinkModel | DirectLink |
LogoURL | https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg |
MergedId | FETCHMERGED-LOGICAL-a414t-bcab361e293ecacf74a1237dad2bdc543b12d7caba583620e475a3268472f97a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-7372-2862 |
PMID | 32787101 |
PQID | 2434060829 |
PQPubID | 23479 |
PageCount | 20 |
ParticipantIDs | crossref_primary_10_1021_acs_jmedchem_0c00691 pubmed_primary_32787101 webofscience_primary_000571493400042 webofscience_primary_000571493400042CitationCount crossref_citationtrail_10_1021_acs_jmedchem_0c00691 acs_journals_10_1021_acs_jmedchem_0c00691 proquest_miscellaneous_2434060829 |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N ACJ VG9 W1F ACS AEESW AFEFF .K2 ABMVS ABUCX IH9 BAANH AQSVZ ED~ UI2 CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-09-10 |
PublicationDateYYYYMMDD | 2020-09-10 |
PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-10 day: 10 |
PublicationDecade | 2020 |
PublicationPlace | WASHINGTON |
PublicationPlace_xml | – name: WASHINGTON – name: United States |
PublicationTitle | Journal of medicinal chemistry |
PublicationTitleAbbrev | J MED CHEM |
PublicationTitleAlternate | J. Med. Chem |
PublicationYear | 2020 |
Publisher | American Chemical Society Amer Chemical Soc |
Publisher_xml | – name: American Chemical Society – name: Amer Chemical Soc |
References | ref17/cit17b ref3/cit3 ref33/cit33a ref17/cit17a ref13/cit13a ref13/cit13b ref27/cit27a ref12/cit12d ref27/cit27b ref12/cit12c ref12/cit12b ref12/cit12a ref23/cit23 ref31/cit31 ref2/cit2 ref33/cit33b ref34/cit34 ref37/cit37 ref20/cit20 ref26/cit26b ref10/cit10 ref16/cit16b ref35/cit35 ref36/cit36a ref16/cit16a ref36/cit36b ref36/cit36c ref19/cit19 ref21/cit21 ref22/cit22a ref26/cit26a ref22/cit22b ref7/cit7b ref7/cit7a ref38/cit38 ref6/cit6 Phillips G. D. L. (ref27/cit27c) 2008; 68 ref18/cit18 ref9/cit9b ref9/cit9a ref11/cit11 ref25/cit25 ref29/cit29 ref8/cit8a ref8/cit8b ref32/cit32 ref14/cit14 ref5/cit5 Ohri R. (ref24/cit24) 2018; 29 ref28/cit28 ref15/cit15 ref30/cit30a ref30/cit30b ref4/cit4 ref1/cit1 Dubowchik, GM (WOS:000077485600013) 1998; 8 Maderna, A (WOS:000355637900011) 2015; 12 Shor, B (WOS:000361922200011) 2015; 67 Ohri, R (WOS:000426144300029) 2018; 29 Choi, J (WOS:000343614800005) 2014; 41 Ogitani, Y (WOS:000384724100022) 2016; 107 Smith, DA (WOS:000359683700001) 2015; 58 Kansy, M (WOS:000072852600001) 1998; 41 Chinchilla, R (WOS:000295037400015) 2011; 40 Zhang, DL (WOS:000387739200005) 2016; 7 Polson, AG (WOS:000264541300028) 2009; 69 EDELMAN, GM (WOS:A1969D694400015) 1969; 63 Erickson, HK (WOS:000236843200060) 2006; 66 Smellie, M (WOS:000184100200014) 2003; 42 Widdison, WC (WOS:000365148700011) 2015; 26 Sutherland, MSK (WOS:000323394300023) 2013; 122 Rettig, M (WOS:000272852100017) 2009; 48 (000571493400042.1) 2018 Li, GM (WOS:000437274600008) 2018; 17 Gschwantler-Kaulich, D (WOS:000367805100041) 2016; 11 Saunders, LR (WOS:000360942300007) 2015; 7 Gregson, SJ (WOS:000486133100043) 2019; 179 Zammarchi, F (WOS:000468819500159) 2018; 78 Adhikari, P (WOS:000561051100005) 2020; 2078 Loomis, K (WOS:000276741000004) 2010; 88 Zheng, B (WOS:000458739900026) 2019; 25 Gregson, SJ (WOS:000418393100006) 2017; 60 Cailleau, T (WOS:000472149500009) 2019; 19 Sookcharoenpinyo, B (WOS:000303506800012) 2012; 51 Caimi, P (WOS:000454842800074) 2018; 132 Hamadani, M (WOS:000454837602304) 2018; 132 Kinneer, K. (000571493400042.24) 2019; 130 Hingorani, DV (WOS:000505667900014) 2020; 19 Costoplus, JA (WOS:000490355900005) 2019; 10 Pillow, TH (WOS:000400713500010) 2017; 16 Kanwal, I (WOS:000537227400008) 2020; 10 Li, F (WOS:000375332300021) 2016; 76 Doronina, SO (WOS:000234905500016) 2006; 17 Phillips, GDL (WOS:000261136600024) 2008; 68 Gregson, SJ (WOS:000189151500011) 2004; 47 Kinneer, K (WOS:000453267600046) 2018; 24 Tohma, H (WOS:000220763400003) 2004; 346 Mantaj, J (WOS:000394996100004) 2017; 56 Rinnerthaler, G (WOS:000462542300114) 2019; 20 DUCHENE, KH (WOS:A1986D711300019) 1986 Reid, EE (WOS:000480500000016) 2019; 10 Jiang, YP (WOS:000439597400008) 2018; 2 Flynn, MJ (WOS:000387546300015) 2016; 15 Pop, LM (WOS:000329297600026) 2014; 74 Dash, BP (WOS:000277445400051) 2010; 132 |
References_xml | – ident: ref25/cit25 doi: 10.1016/j.yexmp.2010.01.006 – ident: ref12/cit12b doi: 10.1021/mp500762u – ident: ref16/cit16b doi: 10.1158/1078-0432.CCR-18-1300 – ident: ref12/cit12d doi: 10.1158/1535-7163.MCT-18-1302 – ident: ref36/cit36c doi: 10.1002/anie.201200447 – ident: ref4/cit4 doi: 10.1126/scitranslmed.aac9459 – volume: 29 start-page: 473 volume-title: Bioconjugate Chem. year: 2018 ident: ref24/cit24 – ident: ref30/cit30a doi: 10.1371/journal.pone.0146311 – ident: ref12/cit12a doi: 10.1021/bc0502917 – ident: ref17/cit17b doi: 10.1021/jm030897l – ident: ref8/cit8a doi: 10.1038/s41375-018-0278-7 – ident: ref16/cit16a doi: 10.2174/1568026619666190401112517 – ident: ref9/cit9b doi: 10.1182/blood-2018-99-118198 – ident: ref11/cit11 – ident: ref30/cit30b doi: 10.1158/0008-5472.CAN-13-1436 – ident: ref33/cit33b doi: 10.1039/c1cs15071e – ident: ref1/cit1 doi: 10.1002/anie.201510610 – ident: ref26/cit26a doi: 10.1016/j.molimm.2014.09.014 – ident: ref13/cit13b doi: 10.1021/acsmedchemlett.9b00310 – ident: ref5/cit5 doi: 10.1182/blood-2013-03-491506 – ident: ref27/cit27b doi: 10.1158/1535-7163.MCT-17-0296 – ident: ref22/cit22b doi: 10.1182/bloodadvances.2018020107 – ident: ref20/cit20 doi: 10.1021/jm970530e – volume: 68 start-page: 9280 year: 2008 ident: ref27/cit27c publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-1776 – ident: ref19/cit19 doi: 10.1021/acsmedchemlett.6b00233 – ident: ref27/cit27a doi: 10.3390/ijms20051115 – ident: ref3/cit3 doi: 10.1158/1535-7163.MCT-16-0641 – ident: ref6/cit6 doi: 10.1182/blood-2018-99-118133 – ident: ref36/cit36a doi: 10.1055/s-1986-31738 – ident: ref37/cit37 – ident: ref9/cit9a doi: 10.1158/1535-7163.MCT-16-0233 – ident: ref26/cit26b doi: 10.1158/0008-5472.CAN-08-2250 – ident: ref34/cit34 doi: 10.1007/978-1-4939-9929-3_4 – ident: ref21/cit21 doi: 10.1016/S0960-894X(98)00609-X – ident: ref10/cit10 – ident: ref23/cit23 doi: 10.1073/pnas.63.1.78 – ident: ref7/cit7a doi: 10.1158/1538-7445.AM2018-2792A – ident: ref2/cit2 doi: 10.1158/1078-0432.CCR-18-0333 – ident: ref18/cit18 doi: 10.1021/acs.jmedchem.7b00736 – ident: ref31/cit31 doi: 10.1021/acs.jmedchem.5b00201 – ident: ref38/cit38 doi: 10.1021/bi901655t – ident: ref33/cit33a doi: 10.3390/catal10040443 – ident: ref14/cit14 doi: 10.1111/cas.12966 – ident: ref35/cit35 doi: 10.1002/adsc.200303203 – ident: ref29/cit29 doi: 10.1158/0008-5472.CAN-05-4489 – ident: ref13/cit13a doi: 10.1021/acs.bioconjchem.5b00430 – ident: ref15/cit15 doi: 10.1021/acsmedchemlett.9b00240 – ident: ref7/cit7b – ident: ref32/cit32 doi: 10.1016/j.nucmedbio.2014.07.005 – ident: ref36/cit36b doi: 10.1021/ja101845m – ident: ref22/cit22a doi: 10.1016/j.ejmech.2019.06.044 – ident: ref28/cit28 doi: 10.1158/1078-0432.CCR-18-1300 – ident: ref8/cit8b – ident: ref12/cit12c doi: 10.1158/0008-5472.CAN-15-1795 – ident: ref17/cit17a doi: 10.1021/bi034313t – volume: 29 start-page: 473 year: 2018 ident: WOS:000426144300029 article-title: High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers publication-title: BIOCONJUGATE CHEMISTRY doi: 10.1021/acs.bioconjchem.7b00791 – volume: 63 start-page: 78 year: 1969 ident: WOS:A1969D694400015 article-title: COVALENT STRUCTURE OF AN ENTIRE GAMMAG IMMUNOGLOBULIN MOLECULE publication-title: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA – volume: 179 start-page: 591 year: 2019 ident: WOS:000486133100043 article-title: Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual beta-glucuronide and dipeptide triggers publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1016/j.ejmech.2019.06.044 – volume: 66 start-page: 4426 year: 2006 ident: WOS:000236843200060 article-title: Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing publication-title: CANCER RESEARCH doi: 10.1158/0008-5472.CAN-05-4489 – volume: 25 start-page: 1358 year: 2019 ident: WOS:000458739900026 article-title: An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia publication-title: CLINICAL CANCER RESEARCH doi: 10.1158/1078-0432.CCR-18-0333 – volume: 2078 start-page: 51 year: 2020 ident: WOS:000561051100005 article-title: Site-Specific Conjugation to Cys-Engineered THIOMAB (TM) Antibodies publication-title: ANTIBODY-DRUG CONJUGATES: METHODS AND PROTOCOLS doi: 10.1007/978-1-4939-9929-3_4 – start-page: 659 year: 1986 ident: WOS:A1986D711300019 article-title: A HYDROCARBON SKELETON WITH 12 IDENTICAL FUNCTIONAL-GROUPS - SYNTHESIS OF A DODECA HOST COMPOUND publication-title: SYNTHESIS-STUTTGART – volume: 78 year: 2018 ident: WOS:000468819500159 article-title: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors publication-title: CANCER RESEARCH doi: 10.1158/1538-7445.AM2018-2792A – volume: 10 start-page: 1193 year: 2019 ident: WOS:000480500000016 article-title: Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs) publication-title: ACS MEDICINAL CHEMISTRY LETTERS doi: 10.1021/acsmedchemlett.9b00240 – volume: 40 start-page: 5084 year: 2011 ident: WOS:000295037400015 article-title: Recent advances in Sonogashira reactions publication-title: CHEMICAL SOCIETY REVIEWS doi: 10.1039/c1cs15071e – volume: 48 start-page: 12223 year: 2009 ident: WOS:000272852100017 article-title: Solution Structure of a Covalently Bound Pyrrolo[2,1-c][1,4]benzodiazepine-Benzimidazole Hybrid to a 10mer DNA Duplex publication-title: BIOCHEMISTRY doi: 10.1021/bi901655t – volume: 41 start-page: 1007 year: 1998 ident: WOS:000072852600001 article-title: Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes publication-title: JOURNAL OF MEDICINAL CHEMISTRY – volume: 58 start-page: 5691 year: 2015 ident: WOS:000359683700001 article-title: Volume of Distribution in Drug Design publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/acs.jmedchem.5b00201 – volume: 130 year: 2019 ident: 000571493400042.24 article-title: Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma publication-title: Leukemia – volume: 69 start-page: 2358 year: 2009 ident: WOS:000264541300028 article-title: Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection publication-title: CANCER RESEARCH doi: 10.1158/0008-5472.CAN-08-2250 – volume: 56 start-page: 462 year: 2017 ident: WOS:000394996100004 article-title: From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs) publication-title: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION doi: 10.1002/anie.201510610 – volume: 107 start-page: 1039 year: 2016 ident: WOS:000384724100022 article-title: Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity publication-title: CANCER SCIENCE doi: 10.1111/cas.12966 – volume: 68 start-page: 9280 year: 2008 ident: WOS:000261136600024 article-title: Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate publication-title: CANCER RESEARCH doi: 10.1158/0008-5472.CAN-08-1776 – volume: 11 start-page: ARTN e0146311 year: 2016 ident: WOS:000367805100041 article-title: HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK publication-title: PLOS ONE doi: 10.1371/journal.pone.0146311 – volume: 8 start-page: 3341 year: 1998 ident: WOS:000077485600013 article-title: Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin publication-title: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS – volume: 10 start-page: 1393 year: 2019 ident: WOS:000490355900005 article-title: Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing publication-title: ACS MEDICINAL CHEMISTRY LETTERS doi: 10.1021/acsmedchemlett.9b00310 – volume: 346 start-page: 111 year: 2004 ident: WOS:000220763400003 article-title: Hypervalent iodine reagents for the oxidation of alcohols and their application to complex molecule synthesis publication-title: ADVANCED SYNTHESIS & CATALYSIS doi: 10.1002/adsc.200303203 – volume: 74 start-page: 263 year: 2014 ident: WOS:000329297600026 article-title: A Reevaluation of CD22 Expression in Human Lung Cancer publication-title: CANCER RESEARCH doi: 10.1158/0008-5472.CAN-13-1436 – volume: 7 start-page: 988 year: 2016 ident: WOS:000387739200005 article-title: Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates publication-title: ACS MEDICINAL CHEMISTRY LETTERS doi: 10.1021/acsmedchemlett.6b00233 – volume: 41 start-page: 802 year: 2014 ident: WOS:000343614800005 article-title: N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization publication-title: NUCLEAR MEDICINE AND BIOLOGY doi: 10.1016/j.nucmedbio.2014.07.005 – volume: 15 start-page: 2709 year: 2016 ident: WOS:000387546300015 article-title: ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies publication-title: MOLECULAR CANCER THERAPEUTICS doi: 10.1158/1535-7163.MCT-16-0233 – volume: 17 start-page: 1441 year: 2018 ident: WOS:000437274600008 article-title: Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells publication-title: MOLECULAR CANCER THERAPEUTICS doi: 10.1158/1535-7163.MCT-17-0296 – volume: 42 start-page: 8232 year: 2003 ident: WOS:000184100200014 article-title: Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: Kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers publication-title: BIOCHEMISTRY doi: 10.1021/bi034313t – volume: 24 start-page: 6570 year: 2018 ident: WOS:000453267600046 article-title: SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads publication-title: CLINICAL CANCER RESEARCH doi: 10.1158/1078-0432.CCR-18-1300 – volume: 47 start-page: 1161 year: 2004 ident: WOS:000189151500011 article-title: Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8 ' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/jm030897l – year: 2018 ident: 000571493400042.1 article-title: Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof publication-title: International patent application – volume: 19 start-page: 157 year: 2020 ident: WOS:000505667900014 article-title: Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability publication-title: MOLECULAR CANCER THERAPEUTICS doi: 10.1158/1535-7163.MCT-18-1302 – volume: 2 start-page: 1738 year: 2018 ident: WOS:000439597400008 article-title: CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia publication-title: BLOOD ADVANCES doi: 10.1182/bloodadvances.2018020107 – volume: 10 start-page: ARTN 443 year: 2020 ident: WOS:000537227400008 article-title: Palladium and Copper Catalyzed Sonogashira cross Coupling an Excellent Methodology for C-C Bond Formation over 17 Years: A Review publication-title: CATALYSTS doi: 10.3390/catal10040443 – volume: 7 start-page: ARTN 302ra136 year: 2015 ident: WOS:000360942300007 article-title: A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo publication-title: SCIENCE TRANSLATIONAL MEDICINE doi: 10.1126/scitranslmed.aac9459 – volume: 132 year: 2018 ident: WOS:000454842800074 article-title: Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study publication-title: BLOOD doi: 10.1182/blood-2018-99-118133 – volume: 60 start-page: 9490 year: 2017 ident: WOS:000418393100006 article-title: Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/acs.jmedchem.7b00736 – volume: 12 start-page: 1798 year: 2015 ident: WOS:000355637900011 article-title: Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates publication-title: MOLECULAR PHARMACEUTICS doi: 10.1021/mp500762u – volume: 20 start-page: ARTN 1115 year: 2019 ident: WOS:000462542300114 article-title: HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer publication-title: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES doi: 10.3390/ijms20051115 – volume: 122 start-page: 1455 year: 2013 ident: WOS:000323394300023 article-title: SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML publication-title: BLOOD doi: 10.1182/blood-2013-03-491506 – volume: 17 start-page: 114 year: 2006 ident: WOS:000234905500016 article-title: Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity publication-title: BIOCONJUGATE CHEMISTRY doi: 10.1021/bc0502917 – volume: 51 start-page: 4586 year: 2012 ident: WOS:000303506800012 article-title: High-Affinity Disaccharide Binding by Tricyclic Synthetic Lectins publication-title: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION doi: 10.1002/anie.201200447 – volume: 88 start-page: 238 year: 2010 ident: WOS:000276741000004 article-title: Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv publication-title: EXPERIMENTAL AND MOLECULAR PATHOLOGY doi: 10.1016/j.yexmp.2010.01.006 – volume: 132 start-page: 6578 year: 2010 ident: WOS:000277445400051 article-title: Synthesis and Properties of Carborane-Appended C-3-Symmetrical Extended pi Systems publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY doi: 10.1021/ja101845m – volume: 67 start-page: 107 year: 2015 ident: WOS:000361922200011 article-title: Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies publication-title: MOLECULAR IMMUNOLOGY doi: 10.1016/j.molimm.2014.09.014 – volume: 19 start-page: 741 year: 2019 ident: WOS:000472149500009 article-title: Potentiation of PBD Dimers by Lipophilicity Manipulation publication-title: CURRENT TOPICS IN MEDICINAL CHEMISTRY doi: 10.2174/1568026619666190401112517 – volume: 76 start-page: 2710 year: 2016 ident: WOS:000375332300021 article-title: Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models publication-title: CANCER RESEARCH doi: 10.1158/0008-5472.CAN-15-1795 – volume: 26 start-page: 2261 year: 2015 ident: WOS:000365148700011 article-title: Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing publication-title: BIOCONJUGATE CHEMISTRY doi: 10.1021/acs.bioconjchem.5b00430 – volume: 16 start-page: 871 year: 2017 ident: WOS:000400713500010 article-title: Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers publication-title: MOLECULAR CANCER THERAPEUTICS doi: 10.1158/1535-7163.MCT-16-0641 – volume: 132 year: 2018 ident: WOS:000454837602304 article-title: Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma publication-title: BLOOD doi: 10.1182/blood-2018-99-118198 |
SSID | ssj0003123 |
Score | 2.4120502 |
Snippet | Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently... Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody-drug conjugates (ADCs), and many examples are currently... |
Source | Web of Science |
SourceID | proquest pubmed webofscience crossref acs |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 9603 |
SubjectTerms | Benzodiazepines - chemistry Binding Sites Cell Line, Tumor Cell Proliferation - drug effects Chemical Phenomena Chemistry, Medicinal Dimerization DNA - chemistry DNA - metabolism Humans Immunoconjugates - adverse effects Immunoconjugates - chemistry Immunoconjugates - metabolism Immunoconjugates - pharmacology Life Sciences & Biomedicine Models, Molecular Nucleic Acid Conformation Pharmacology & Pharmacy Pyrroles - chemistry Safety Science & Technology |
Title | Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates |
URI | http://dx.doi.org/10.1021/acs.jmedchem.0c00691 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000571493400042 https://www.ncbi.nlm.nih.gov/pubmed/32787101 https://www.proquest.com/docview/2434060829 |
Volume | 63 |
WOS | 000571493400042 |
WOSCitedRecordID | wos000571493400042 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQOcCFR3mFl4xUVVRqtontXZNjybYqSECkblFvkR070NImqyR72D3xH_gf_Ch-CTNOsgsU1HJNbOcx45lvbM83hGzk0oxyJSPf5Ln1hQqUr4aC-1mUCTmKNM8VZiO_ez86OBJvj4fHq0Dxzx18Fu6orB6c4mHFz_Z8EGRIrQvRznU2gnmMUCg-XFpeHjLes4Mz8Ot9qtw_RkGHlNW_O6QLKPOvDsk5n_3b5EOfwtOeOfkymDV6kC0uMjpe8bvukFsdDqW7reLcJddssU5uxH35t3WymbSk1vNtOlnlaNXbdJMmK7rr-T3y_XBJBk0_QuTtRE3LnCbzqirxMEexKEELF3YKiJa-TF6Pt_zxybmtaILLBcpQdww1w9pdjryAJrhDUCHVK33jsjhruodUF_A2VBWGTsozeCN3rHeOTwIQS2NXZmRauiwduls0J7o08x9fv42r2Se4W5zOcMWwvk-O9vcm8YHfVYHwlQhF4-tMaT4KLeASC8_JpVAgZmmUYdpkoFc6ZEZCIzV8Bd44sEIOFUcSG8nySCr-gKwVZWEfEQrmJsh5NIyMttAPoJlQkdKWQ5QrmJYe2QKppN0srlO3Qc_C1F3sRJV2ovII79UmzTo6dazqcXZJL3_Za9rSiVzS_kWvkSnIHzdzVGHLWZ0ywQGLYWa0Rx62qrockTMww2BrPbLxq-4u7yNQlxAawwhotD0SXqVZ3H0lkiU0j__jVz0hNxmuUmDhjeApWWuqmX0GUK7Rz938_QlAREqE |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwELYQPdBLH_S1fboSQkUiS2I76-a43QUtLaBILIhbZCdOC4VklWQPu6f-h_6P_qj-ks54k2yfolwT23Eyk5nP9sw3hGykMumlSgZOkqbGEcpVjvIFd-IgFrIXaJ4qzEY-POqNTsT7M_9shfhNLgxMooSRSnuIv2QX8Hbw2gXGLH4yV103RoZdWPTcAjzCULH7g-PWAHOP8YYknIF7bzLm_jEK-qW4_NUv_QE2_-qXrA_au0tO29nb0JPP3Wmlu_H8N2LHG7_ePXKnRqW0v1Cj-2TFZOtkbdAUg1snm-GC4nq2TcfLjK1ym27ScEl-PXtAvh231ND0FNbhVvA0T2k4K4ocQzuyeQ46OTcTwLf0TfhuuOUMz69MQUPcPFAJtUGpMVbyslQGNMTzggKJX-m-zeks6S4SX8BsqMoSOs4vYUY2yHeGTwJISwe26Mgktzk7tJ9V5zpPZt-_fB0W049wN7uY4v5h-ZCc7O2OByOnrgnhKOGJytGx0rznGUApBp6TSqFA2jJRCdNJDFqmPZZIaKT8t-CbXSOkrzhS2kiWBlLxR2Q1yzPzhFAwPm7KAz9ItIF-ANSECpQ2HNa8gmnZIVsglaj-p8vIHtczL7IXa1FFtag6hDfaE8U1uTrW-Li8ppfT9posyEWuaf-6UcwI5I9HOyoz-bSMmOCAzDBPukMeLzS2HZEzMMpgeTtk42cVbu8jbJewUIYR0IR3iPc_zQb1WyJ1QvX0Bp_qFVkbjQ8PooP9ow_PyG2G-xdYksN9TlarYmpeAMir9Ev7S_8AFu9S5Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQkYALj_IKTyNVFZWaJbG9a3JcdrtqeVSRukVVL5EdO9DSJqske9g98R_4H_wofgkz3mxaXipwTWzHzoxnxp6ZbwhZy6TpZUpGvsky6wsVKF91BffTKBWyF2meKcxGfrfb294Xrw-6B-dKfcEkKhipck583NUTkzUIA-ELfH6McYsf7WknSBFlFw4-l9Fzh8zdH-y1QpiHjC-Bwhmo-GXW3B9GQd2UVj_qpl8Mzt_qJqeHRjfIYbsCF37yqTOtdSed_wTu-F9LvEmuN9Yp7S_Y6Ra5ZPNVcnWwLAq3StbjBdT1bJOOzzK3qk26TuMzEOzZbfJ1r4WIpu_hPO4YgBYZjWdlWWCIRz4vgDfndgJ2Ln0evxpu-MOjU1vSGC8RlKEuODXFil4O0oDG6DcoEQCW7rjczopuIQAGzIaq3NBxcQIzcsG-M_wSmLZ04IqPTAqXu0P7eX2kCzP79vnLsJx-gLf58RTvEas7ZH-0NR5s-01tCF-JUNS-TpXmvdCCtWLhO5kUCigujTJMmxS4TYfMSGikui9BRwdWyK7iCG0jWRZJxe-SlbzI7X1CQQgFGY-6kdEW-oHBJlSktOVw9hVMS49sAFWSZm9XiXPbszBxDxtSJQ2pPMKXHJSkDcg61vo4uaCX3_aaLEBGLmj_bMmcCdAfXTwqt8W0SpjgYKFhvrRH7i24th2RMxDOIIE9snaejdv3aL5LODDDCCjKPRL-TbNBs0qEUKgf_MOvekquxMNR8nZn981Dco3hNQZW5ggekZW6nNrHYOvV-onb1d8BqCZVaA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systematic+Variation+of+Pyrrolobenzodiazepine+%28PBD%29-Dimer+Payload+Physicochemical+Properties+Impacts+Efficacy+and+Tolerability+of+the+Corresponding+Antibody%E2%80%93Drug+Conjugates&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Staben%2C+Leanna+R&rft.au=Chen%2C+Jinhua&rft.au=Cruz-Chuh%2C+Josefa+dela&rft.au=del+Rosario%2C+Geoff&rft.date=2020-09-10&rft.pub=American+Chemical+Society&rft.issn=0022-2623&rft.eissn=1520-4804&rft.volume=63&rft.issue=17&rft.spage=9603&rft.epage=9622&rft_id=info:doi/10.1021%2Facs.jmedchem.0c00691&rft.externalDocID=c500932642 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon |